|
| Press Releases |
|
 |
|
| Thursday, April 24, 2025 |
|
|
HighTide Therapeutics to Showcase New Analyses of Phase 2 MASH/T2DM Studies of Berberine Ursodeoxycholate (HTD1801) and Pre-Clinical Results of Rimtoregtide (HTD4010) in Presentations at EASL Congress 2025 |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the EASL Congress 2025, taking place from May 7-10, 2025 in Amsterdam. more info >> |
|
|
君圣泰医药三项创新研究成果即将亮相2025欧肝会(EASL) |
| 君圣泰医药（股票代码: 2511.HK），一家专注于开发多功能创新疗法以解决代谢性疾病未满足临床需求的医药公司，今日宣布将于欧洲肝脏研究协会（EASL）2025年大会（5月7日-10日，荷兰阿姆斯特丹）上发表三项研究成果，分别为熊去氧胆小檗碱（HTD1801，一种全球首创的靶向肠-肝系统的抗炎及代谢调节剂）针对代谢相关脂肪性肝炎（MASH）治疗的临床2期研究事后分析结果、针对2型糖尿病（T2DM）治疗的临床2期研究事后分析结果，以及Rimtoregtide（HTD4010，一种Reg3α衍生肽）在肝衰竭小鼠中的临床前研究结果。 more info >> |
|
| Tuesday, April 15, 2025 |
|
|
Berberine Ursodeoxycholate (HTD1801) Consistently Demonstrates Comprehensive Benefits for Patients with Type 2 Diabetes Mellitus, Approaching NDA |
| HighTide Therapeutics, Inc. (2511.HK), a clinical-stage biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic liver and metabolic diseases, today announced that two Phase 3 trials (SYMPHONY 1 and SYMPHONY 2) of berberine ursodeoxycholate (HTD1801) in Chinese patients with type 2 diabetes mellitus (T2DM) met their primary endpoints and gated secondary endpoints. more info >> |
|
|
熊去氧膽小檗堿（HTD1801）一藥多效 即將進入商業化新紀元 |
| 君聖泰醫藥（股票代碼: 2511.HK），一家專注于開發多功能創新療法以解決慢性肝病和代謝性疾病未滿足臨床需求的醫藥公司，今日宣佈，熊去氧膽小檗堿（HTD1801）在中國2型糖尿病（T2DM）患者中開展的兩項3期臨床試驗（SYMPHONY 1和SYMPHONY 2）達到主要療效終點及多個次要療效終點。 more info >> |
|
|
熊去氧胆小檗碱（HTD1801）一药多效 即将进入商业化新纪元 |
| 君圣泰医药（股票代码: 2511.HK），一家专注于开发多功能创新疗法以解决慢性肝病和代谢性疾病未满足临床需求的医药公司，今日宣布，熊去氧胆小檗碱（HTD1801）在中国2型糖尿病（T2DM）患者中开展的两项3期临床试验（SYMPHONY 1和SYMPHONY 2）达到主要疗效终点及多个次要疗效终点。 more info >> |
|
| Thursday, March 20, 2025 |
|
|
MASH疾病領域的大市場、大需求 |
| 代謝相關脂肪性肝炎（MASH）已成為全球醫藥行業正在挖掘的潛力「富礦」——2030年MASH市場規模將突破322億美元，患者人數超4.8億，至今FDA僅批准了一款藥物。MASH作為一種與代謝紊亂相關的肝臟疾病，表現為肝臟中脂肪異常堆積，並伴隨炎症和肝臟纖維化，可進展為肝硬化和肝細胞癌，是全球肝移植的主要病因，更顯著增加了心血管疾病的風險。 more info >> |
|
| Wednesday, March 19, 2025 |
|
|
MASH疾病领域的大市场、大需求 |
| 代谢相关脂肪性肝炎（MASH）已成为全球医药行业正在挖掘的潜力“富矿”——2030年MASH市场规模将突破322亿美元，患者人数超4.8亿，至今FDA仅批准了一款药物。 more info >> |
|
| Tuesday, March 4, 2025 |
|
|
重磅發佈 - 君聖泰醫藥在JAMA Network Open發表熊去氧膽小檗鹼治療2型糖尿病的臨床2期研究數據 療效顯著 多重代謝獲益 市場前景廣闊 |
| 中國深圳、美國馬里蘭州羅克維爾，君聖泰醫藥（股票代碼: 2511.HK），一家專注于開發多功能多靶點創新療法、解決代謝性疾病及慢性肝病未滿足臨床需求的醫藥公司，今日宣佈，熊去氧膽小檗堿（HTD1801）治療2型糖尿病（T2DM）的臨床2期研究結果在期刊JAMA Network Open發表。 more info >> |
|
|
HighTide Therapeutics Announces Publication of Phase 2 Study of Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes Mellitus in JAMA Network Open |
| HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, today announced that data from the Phase 2 proof-of-concept study evaluating berberine ursodeoxycholate (HTD1801) for the treatment of type 2 diabetes mellitus (T2DM) was published online in JAMA Network Open. more info >> |
|
|
重磅发布 - 君圣泰医药在JAMA Network Open发表熊去氧胆小檗碱治疗2型糖尿病的临床2期研究数据 疗效显著 多重代谢获益 市场前景广阔 |
| 君圣泰医药（股票代码: 2511.HK），一家专注于开发多功能多靶点创新疗法、解决代谢性疾病及慢性肝病未满足临床需求的医药公司，今日宣布，熊去氧胆小檗碱（HTD1801）治疗2型糖尿病（T2DM）的临床2期研究结果在期刊JAMA Network Open发表。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China
Mar 13, 2026 23:00: JST
|
|
|
General MRO Aerospace 取得中國民航局認證，拓展全球維修能力
Mar 13, 2026 22:20 HKT/SGT
|
|
|
General MRO Aerospace 获得中国民航局认证，拓展全球维护能力
Mar 13, 2026 22:20 HKT/SGT
|
|
|
General MRO Aerospace Achieves CAAC Certification, Expanding Global Maintenance Capabilities
Mar 13, 2026 22:20 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China
Mar 13, 2026 22:00 HKT/SGT
|
|
|
CITIC Resources Deepens Dual-Engine Strategy of 'Investment + Trading', Continues to Promote High-Quality Development
Mar 13, 2026 21:01 HKT/SGT
|
|
|
中信資源深化「投資+貿易」雙輪戰略 持續驅動高質量發展 推進「上游資產布局、貿易業務拓展、生產運營提質」
Mar 13, 2026 20:53 HKT/SGT
|
|
|
中信资源深化「投资+贸易」双轮战略 持续驱动高质量发展 推进「上游资产布局、贸易业务拓展、生产运营提质」
Mar 13, 2026 20:40 HKT/SGT
|
|
|
康哲藥業：腎性貧血新藥德昔度司他片中國獲批上市
Mar 13, 2026 20:24 HKT/SGT
|
|
|
康哲药业：肾性贫血新药德昔度司他片中国获批上市
Mar 13, 2026 20:15 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
Mar 13, 2026 18:00: JST
|
|
|
uSMART HK Expands to 12 Physical Service Centres in One Year, Accelerating "Online x Offline" O2O Community Finance Strategy
Mar 13, 2026 17:34 HKT/SGT
|
|
|
盈立證券一年拓展12個服務網點 全力深化「線上x線下」O2O社區金融佈局
Mar 13, 2026 17:21 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream (Lumirix(R)) Achieves Initial Prescriptions in Multiple Regions in China for Patients with Vitiligo
Mar 13, 2026 17:00 HKT/SGT
|
|
|
盈立证券一年拓展12个服务网点 全力深化「在线x线下」O2O小区金融布局
Mar 13, 2026 16:56 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
